Cite

    Blauvelt, A. et al. (2021). A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial. British journal of dermatology. pp. 1047-1058. [Online].